

Amendments to the Claims:

1. (Currently amended) A method for treating an immune system disorder in a subject in need of such treatment, wherein the disorder is ~~selected from the group consisting of HIV infection, AIDS, and or~~ adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID), comprising administering to said subject a compound selected from the group consisting of:

- (a) selective A₁ adenosine receptor antagonists;
 - (b) selective P_{2X} purinoceptor antagonists; and
 - (c) a combination of at least one A₁ adenosine receptor antagonist and at least one P_{2X} purinoceptor antagonist;
- wherein said compound is administered in an amount effective to treat the immune system disorder.

2. (Canceled)

3. (Original) A method according to Claim 1, wherein the A₁ adenosine receptor antagonist is an antibody that binds the A₁ adenosine receptor.

4. (Original) A method according to Claim 1, wherein the P_{2X} purinoceptor antagonist is an antibody that binds the P_{2X} purinoceptor.

5. (Currently amended) A method for preventing or delaying the onset of an immune system disorder in a subject in need of such treatment, wherein the disorder is ~~selected from the group consisting of HIV infection, AIDS, and or~~ ADA SCID, comprising administering to said subject a compound selected from the group consisting of:

- (a) selective A₁ adenosine receptor antagonists;
- (b) selective P_{2X} purinoceptor antagonists; and

(c) a combination of at least one A₁ adenosine receptor antagonist and at least one P_{2x} purinoceptor antagonist;
wherein said compound is administered in an amount effective to prevent or delay the onset of the immune system disorder that would occur in the absence of the administration.

6. (Canceled)

7. (Original) The method according to Claim 5, wherein the A₁ adenosine receptor antagonist is an antibody that binds to the A₁ adenosine receptor.

8. (Original) A method according to Claim 5, wherein the P_{2x} purinoceptor antagonist is an antibody that binds to the P_{2x} purinoceptor.

9. (Canceled)

10. (Currently amended) The method of Claim 1, wherein the treatment is carried out in conjunction with another treatment for ~~HIV-infection~~, AIDS[[,]] or ADA SCID.

Claims 11-23 (Canceled)

24. (Previously presented) The method according to claim 1, wherein the immune system disorder is AIDS.

25. (Previously presented) The method according to claim 1, wherein the immune system disorder is ADA SCID.

26. (Canceled)

27. (Previously presented) The method according to claim 5, wherein the immune system disorder is AIDS.

28. (Previously presented) The method according to claim 5, wherein the immune system disorder is ADA SCID.

29. (New) A method for preventing or treating HIV infection in a subject, said method comprising administering to said subject a compound selected from the group consisting of:

- (a) selective A₁ adenosine receptor antagonists;
 - (b) selective P_{2X} purinoceptor antagonists; and
 - (c) a combination of at least one A₁ adenosine receptor antagonist and at least one P_{2X} purinoceptor antagonist;
- wherein said compound is administered in an amount effective to prevent or treat HIV infection.

30. (New) A method according to Claim 29, wherein the A₁ adenosine receptor antagonist is an antibody that binds the A₁ adenosine receptor.

31. (New) A method according to Claim 29, wherein the P_{2X} purinoceptor antagonist is an antibody that binds the P_{2X} purinoceptor.

32. (New) The method of Claim 29, wherein the treatment is carried out in conjunction with another treatment for HIV infection.